Reversal of Immunosenescence

What is the most undervalued area for longevity progress we should pursue?Reversal of immunosenescence could be accomplished through adoptive T-cell transfer from a bank of universal induced immature T-cells with ex-vivo maturation and selection within an autologous iPSC-derived ex vivo thymus.Where are we today? Where would we like to be?Autologous CAR-T cell production is an FDA-approved therapy for several hematological cancers. Commercial scale production of master cell banks of genetically-modified induced T&NK cells is in US trials. Human thymus organoid production has proof of concept. Production of iPSC-derived thymi and in-vitro thymopoiesis in mice has been published.What public and private actions have the biggest impact on those goals?An academic or industry group needs to assemble the proper iPSC-derived universal donor cell bank. There should be a GMP iT differentiation process from that bank, as well as GMP autologous iPSC-derived thymus organoid generation. There should also be a GMP in-vitro thymopoiesis process in preparation for an IND filing.What people, funding, resources, experiments would be required to test this hypothesis?We need personnel with universal donor genetic engineering expertise, iPSC-derived cell bank manufacturing expertise, and personnel with experience growing thymus organoids and using them for in-vitro thymopoiesis. These processes need to be translated to clinical-scale GMP processes.